Nanotech Investing Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma 23 October
Nanotech Investing Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 20 October
Nanotech Investing NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street 08 October
